Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640469 | 0.80 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2288939 | 0.74 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2895136 | 0.71 | NPC1 (0.65) | RAB9ANPC1ALDH1A1FAAHKDM4E | |
| SCHEMBL13028753 | 0.71 | NPC1 (0.65) | RAB9ANPC1ALDH1A1FAAHKDM4E | |
| SCHEMBL2895139 | 0.71 | NPC1 (0.65) | RAB9ANPC1ALDH1A1FAAHKDM4E | |
| SCHEMBL28635395 | 0.69 | KMT2A (0.47) | RAB9ANPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2095091 | 0.67 | SMN1; SMN2 (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1FAAH | |
| SCHEMBL2291115 | 0.66 | ALDH1A1 (0.61) | RAB9ANPC1ALDH1A1GAAFAAH | |
| SCHEMBL2095089 | 0.66 | ALDH1A1 (0.55) | RAB9ANPC1ALDH1A1GAAFAAH | |
| SCHEMBL9425626 | 0.65 | MEN1 (0.31) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | RAB9A 2436/4885NPC1 1113/4885SMN1; SMN2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.